Unraveling Survival Determinants in Patients with Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions
EGFR-TKIs may be considered as an alternative treatment option for patients with <i>EGFR</i> exon 20 insertions in cases where the currently recommended therapies, such as chemotherapy with or without amivantamab, are either unavailable or intolerable. The potential use of afatinib for specific patients in this context depends on the precise characteristics of their mutation and remains to be determined.
Authors
- K. Wang
- Yu‐Feng Wei (ORCID: https://orcid.org/0000-0002-6380-3527)
- Jui-Chi Hung
- Chung‐Yu Chen (ORCID: https://orcid.org/0000-0001-9002-7255)
- Cheng‐Yu Chang (ORCID: https://orcid.org/0000-0002-7196-3504)
- Shih-Chieh Chang (ORCID: https://orcid.org/0009-0006-4470-1783)
Institutions
- National Yang Ming Chiao Tung University (TW)
- Far Eastern Memorial Hospital (TW)
- National Taiwan University Hospital (TW)
- National Yunlin University of Science and Technology (TW)
- I-Shou University (TW)
- Yuan Ze University (TW)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-03-18
- DOI
- https://doi.org/10.3390/curroncol32030174
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00